BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Preston IR, Burger CD, Bartolome S, Safdar Z, Krowka M, Sood N, Ford HJ, Battarjee WF, Chakinala MM, Gomberg-Maitland M, Hill NS. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial. J Heart Lung Transplant 2020;39:464-72. [PMID: 32008947 DOI: 10.1016/j.healun.2019.12.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Xu H, Cheng B, Wang R, Ding M, Gao Y. Portopulmonary hypertension: Current developments and future perspectives. Liver Research 2022. [DOI: 10.1016/j.livres.2022.02.002] [Reference Citation Analysis]
2 Jose A, Kay D, Elwing JM. Treatment of Portopulmonary Hypertension (PoPH): A Review. Journal of Liver Transplantation 2022. [DOI: 10.1016/j.liver.2022.100071] [Reference Citation Analysis]
3 DuBrock HM, Krowka MJ. The Myths and Realities of Portopulmonary Hypertension. Hepatology 2020;72:1455-60. [PMID: 32515501 DOI: 10.1002/hep.31415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
4 DuBrock HM, Burger CD, Bartolome SD, Feldman JP, Ivy DD, Rosenzweig EB, Sager JS, Presberg KW, Mathai SC, Lammi MR, Klinger JR, Eggert M, De Marco T, Elwing JM, Badesch D, Bull TM, Cadaret LM, Ramani G, Thenappan T, Ford HJ, Al-Naamani N, Simon MA, Mazimba S, Runo JR, Chakinala M, Horn EM, Ryan JJ, Frantz RP, Krowka MJ. Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. Pulm Circ 2021;11:20458940211020913. [PMID: 34158918 DOI: 10.1177/20458940211020913] [Reference Citation Analysis]
5 Del Valle K, DuBrock HM. Hepatopulmonary Syndrome and Portopulmonary Hypertension: Pulmonary Vascular Complications of Liver Disease. Compr Physiol 2021;11:1-22. [PMID: 34636408 DOI: 10.1002/cphy.c210009] [Reference Citation Analysis]
6 Yu Z, Xiao J, Chen X, Ruan Y, Chen Y, Zheng X, Wang Q. Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension. Chin Med 2022;17. [DOI: 10.1186/s13020-022-00568-w] [Reference Citation Analysis]
7 Burger CD, DuBrock HM, Cartin-Ceba R, Moss JE, Shapiro BP, Frantz RP. Topic-Based, Recent Literature Review on Pulmonary Hypertension. Mayo Clin Proc 2021:S0025-6196(21)00437-7. [PMID: 34479734 DOI: 10.1016/j.mayocp.2021.05.026] [Reference Citation Analysis]
8 Nair A. Pharmacologic therapy for pulmonary artery hypertension. Curr Opin Cardiol 2020;35:643-56. [PMID: 32897888 DOI: 10.1097/HCO.0000000000000796] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Thomas C, Glinskii V, de Jesus Perez V, Sahay S. Portopulmonary Hypertension: From Bench to Bedside. Front Med (Lausanne) 2020;7:569413. [PMID: 33224960 DOI: 10.3389/fmed.2020.569413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]